Phage Therapy: Various Perspectives on How to Improve the Art

  • Stephen T. AbedonEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1734)


Use of phages as antibacterial agents has a long and, even, storied history. During that time much has been learned but, to a degree, also forgotten. As a consequence, today we experience a largely preclinical development of a field which already has been subject to substantial clinical practice. This development, as well, is now occurring within a much more rigorously regulated environment than previously had been the case. The consequence is not only a need to reinvent standards of practice but to do so within a more explicitly pharmacological context. Of particular concern is that the application of phages to bacterial infections does not always result in control of the latter, necessitating ongoing thought on how to refine treatment protocols. Here I consider a number of issues relevant to such refinement, focusing on areas which, in my opinion, phage therapy researchers—perhaps especially those new to the field—might struggle with. In order of presentation, I consider how best to describe phage therapy within publications toward achieving a more coherent literature, the importance of Poisson distributions along with killing titers toward understanding phage dosing, the associated importance of establishing sufficient phage numbers in situ to achieve adequate bacteria killing, various problems with the use of multiplicity of infection (MOI) as a description of phage dosing, how to anticipate the basic kinetics of phage–bacteria absorptive interactions, how to distinguish passive from active treatments, and basic approaches toward addressing disappointing efficacy outcomes.

Key words

Bacteriophage therapy Biocontrol Biocontrol using phages Biological control Killing titer Multiplicity of infection Phage biocontrol Phage therapy Phage therapy pharmacology Poisson distribution 


  1. 1.
    Clokie MRJ, Kropinski AM (2009) Preface. In: Clokie MRJ, Kropinski AM (eds) Bacteriophages: methods and protocols. Springer, New York, NYGoogle Scholar
  2. 2.
    McAuliffe O, Ross RP, Fitzgerald GF (2007) The new phage biology: from genomics to applications. In: Mc Grath S, van Sinderen D (eds) Bacteriophage: genetics and microbiology. Caister Academic Press, Norfolk, pp 1–41Google Scholar
  3. 3.
    Young R (2014) Phage lysis: three steps, three choices, one outcome. J Microbiol 52:243–258CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Alberts BM (1994) Epilogue: unsolved mysteries and the T4 paradigm. In: Karam JD (ed) Molecular biology of bacteriophage T4. ASM Press, Washington, DC, pp 487–488Google Scholar
  5. 5.
    Weinbauer MG (2004) Ecology of prokaryotic viruses. FEMS Microbiol Rev 28:127–181CrossRefPubMedGoogle Scholar
  6. 6.
    Goyal SM, Gerba CP, Bitton G (1987) Phage ecology. CRC Press, Boca Raton, FLGoogle Scholar
  7. 7.
    Abedon ST (2017) Bacteriophage clinical use as antibactertial “drugs”: utility precident. In: Cani P, Britton R (eds) Bugs as drugs. American Society for Microbiology, Washington, DCGoogle Scholar
  8. 8.
    Abedon ST (2012) Phage therapy best practices. In: Hyman P, Abedon ST (eds) Bacteriophages in health and disease. CABI Press, Wallingford, pp 256–272CrossRefGoogle Scholar
  9. 9.
    Abedon ST (2009) Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis 6:807–815CrossRefPubMedGoogle Scholar
  10. 10.
    Ackermann HW (2011) Phage or phages. Bacteriophage 1:52–53CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Abedon ST, Katsaounis TI (2017) Basic phage mathematics. Methods in molecular biology. Springer, New York, NYGoogle Scholar
  12. 12.
    Dulbecco R (1949) Appendix: on the reliability of the Poisson distribution as a distribution of the number of phage particles infecting individual bacteria in a population. Genetics 34:122–125Google Scholar
  13. 13.
    Stent GS (1963) Molecular biology of bacterial viruses. WH Freeman and Co., San Francisco, CAGoogle Scholar
  14. 14.
    Carlson K (2005) Working with bacteriophages: common techniques and methodological approaches. In: Kutter E, Sulakvelidze A (eds) Bacteriophages: biology and application. CRC Press, Boca Raton, FL, pp 437–494Google Scholar
  15. 15.
    Abedon ST (2011) Bacteriophages and biofilms: ecology, phage therapy, plaques. Nova Science Publishers, Hauppauge, NYGoogle Scholar
  16. 16.
    Abedon ST (2016) Phage therapy dosing: the problem(s) with multiplicity of infection (MOI). Bacteriophage 6:e1220348CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Abedon S (2011) Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol 77:1–40CrossRefPubMedGoogle Scholar
  18. 18.
    Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11:28–47CrossRefPubMedGoogle Scholar
  19. 19.
    Abedon ST (2014) Bacteriophages as drugs: the pharmacology of phage therapy. In: Borysowski J, Miedzybrodzki R, Górski A (eds) Phage therapy: current research and applications. Caister Academic Press, Norfolk, pp 69–100Google Scholar
  20. 20.
    Kasman LM, Kasman A, Westwater C et al (2002) Overcoming the phage replication threshold: a mathematical model with implications for phage therapy. J Virol 76:5557–5564CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hagens S, Loessner MJ (2010) Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 11:58–68CrossRefPubMedGoogle Scholar
  22. 22.
    Abedon ST (2015) Ecology of anti-biofilm agents II. Bacteriophage exploitation and biocontrol of biofilm bacteria. Pharmaceuticals 8:559–589CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Goodridge LD (2008) Phages, bacteria, and food. In: Abedon ST (ed) Bacteriophage ecology. Cambridge University Press, Cambridge, pp 302–331CrossRefGoogle Scholar
  24. 24.
    Abedon ST (1990) Selection for lysis inhibition in bacteriophage. J Theor Biol 146:501–511CrossRefPubMedGoogle Scholar
  25. 25.
    Payne RJH, Phil D, Jansen VAA (2000) Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 68:225–230CrossRefPubMedGoogle Scholar
  26. 26.
    Payne RJH, Jansen VAA (2001) Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 208:37–48CrossRefPubMedGoogle Scholar
  27. 27.
    Payne RJH, Jansen VAA (2003) Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet 42:315–325CrossRefPubMedGoogle Scholar
  28. 28.
    Abedon ST (2014) Phage therapy: eco-physiological pharmacology. Scientifica 2014:581639CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Gill JJ, Young R (2011) Therapeutic applications of phage biology: history, practice and recommendations. In: Miller AA, Miller PF (eds) Emerging trends in antibacterial discovery: answering the call to arms. Caister Academic Press, Norfolk, pp 367–410Google Scholar
  30. 30.
    Abedon ST (2011) Lysis from without. Bacteriophage 1:46–49CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Furuya Y, Wijesundara DK, Neeman T et al (2014) Use and misuse of statistical significance in survival analyses. MBio 5:e00904CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Singla S, Harjai K, Katare OP et al (2016) Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS One 11:e0153777CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Colom J, Cano-Sarabia M, Otero J et al (2015) Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol 81:4841–4849CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Abedon ST (2015) Phage therapy of pulmonary infections. Bacteriophage 5:e1020260CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Miedzybrodzki R, Borysowski J, Weber-Dabrowska B et al (2012) Clinical aspects of phage therapy. Adv Virus Res 83:73–121CrossRefPubMedGoogle Scholar
  36. 36.
    Kutter EM, Kuhl SJ, Abedon ST (2015) Re-establishing a place for phage therapy in western medicine. Future Microbiol 10:685–688CrossRefPubMedGoogle Scholar
  37. 37.
    Abedon ST (2017) Information phage therapy research should report. Pharmaceuticals (Basel) 10:43CrossRefGoogle Scholar
  38. 38.
    Abedon ST (2017) Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes. AIMS Microbiol 3:649–688CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Department of MicrobiologyThe Ohio State UniversityMansfieldUSA

Personalised recommendations